3
Announcements
Trials
Browse
Landscape
Status
Available
2
No longer available
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
384
Observational
43
Expanded_access
3
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia, Myeloid, Acute
7
Myelodysplastic Syndromes
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Primary Myelofibrosis
3
Lymphoma
3
Leukemia
3
Hematologic Neoplasms
3
Blast Crisis
3
Precancerous Conditions
2
Polycythemia Vera
2
Multiple Myeloma
2
Mastocytosis, Systemic
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Mast-Cell
2
Immunologic Deficiency Syndromes
2
Graft vs Host Disease
2
Waldenstrom Macroglobulinemia
1
Thalassemia
1
Sarcoma
1
Recurrence
1
Preleukemia
1
Pancytopenia
1
Osteosclerosis
1
Osteopetrosis
1
Osteochondrodysplasias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Interventions
venetoclax
1
selinexor
1
ruxolitinib
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Expanded_access
×
Primary Myelofibrosis
×
Myeloid
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT04745637
2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available